Literature DB >> 11252543

The cost of HIV treatment and care. A global review.

E J Beck1, A H Miners, K Tolley.   

Abstract

This review of published studies on the costs of HIV treatment and care describes some of the recent developments that have influenced these costs in industrialised and industrialising countries, especially within the context of changing drug treatments. Some of the different approaches to estimating the economic impact of HIV infection are briefly presented. The methods used to review the literature are described, particularly the criteria of a scoring system that was specifically developed to systematically screen some of the studies identified. The mean review score for studies dealing with direct hospital costs increased significantly (p = 0.003) over the 3 periods analysed (before 1987, 1987 to 1995, and 1996 and beyond), indicating that the overall 'quality' of studies increased over time. All cost estimates, other than those from non-industrialised regions, were converted to 1996 US dollars using country-specific total health expenditure inflaters and country-specific Gross Domestic Product Purchasing Power Parity converters. A summary of hospital cost estimates over time and by region demonstrated that the costs of treating asymptomatic individuals and people with symptomatic non-AIDS increased over the period, but that the costs of treating individuals with AIDS appears to have stabilised since the late 1980s. As fewer studies could be identified on the costs of community and informal care, indirect productivity costs and population cost estimates, and costs of care for children with HIV infection, all of these studies were reviewed without the use of the scoring system. Finally, the discussion explores the evidence on the global costs of HIV in non-industrialised economies and the affordability of HIV treatment and care. Some suggestions for the direction of future HIV costing studies are also presented. A need remains for good quality cost data. Adequate research effort should be directed to improving the scope and quality of information on costs of HIV service provision around the world.

Entities:  

Mesh:

Year:  2001        PMID: 11252543     DOI: 10.2165/00019053-200119010-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  102 in total

1.  Comparisons of hospital care for patients with AIDS and other HIV-related conditions.

Authors:  D P Andrulis; V B Weslowski; E Hintz; A W Spolarich
Journal:  JAMA       Date:  1992-05-13       Impact factor: 56.272

2.  Decline in deaths from AIDS due to new antiretrovirals.

Authors:  R S Hogg; M V O'Shaughnessy; N Gataric; B Yip; K Craib; M T Schechter; J S Montaner
Journal:  Lancet       Date:  1997-05-03       Impact factor: 79.321

3.  The economic costs of caring for people with HIV infection and AIDS in England and Wales.

Authors:  S Petrou; M Dooley; L Whitaker; E Beck; E Kupek; J Wadsworth; D Miller; A Renton
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

4.  Lifetime cost of care for children with human immunodeficiency virus infection.

Authors:  P L Havens; B E Cuene; D R Holtgrave
Journal:  Pediatr Infect Dis J       Date:  1997-06       Impact factor: 2.129

Review 5.  The treatment and care costs of people with HIV infection or AIDS: development of a standardised cost framework for Europe.

Authors:  K Tolley; M Gyldmark
Journal:  Health Policy       Date:  1993-04       Impact factor: 2.980

6.  Paediatric treatment costs and the HIV epidemic.

Authors:  E Nelson; M Weikert; J A Phillips
Journal:  Cent Afr J Med       Date:  1995-05

7.  Medical care costs of patients with AIDS in Hawaii.

Authors:  F K Abou-Sayf; J R Marzolf
Journal:  Hawaii Med J       Date:  1989-05

8.  Costs of HIV medical care in the era of highly active antiretroviral therapy.

Authors:  K A Gebo; R E Chaisson; J G Folkemer; J G Bartlett; R D Moore
Journal:  AIDS       Date:  1999-05-28       Impact factor: 4.177

9.  Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States, 1985, 1986, and 1991.

Authors:  A A Scitovsky; D P Rice
Journal:  J Med Pract Manage       Date:  1988

10.  Financing HIV service provision in England: estimated impact of the cost of antiretroviral combination therapy.

Authors:  E J Beck; K Tolley
Journal:  Int J STD AIDS       Date:  1998-09       Impact factor: 1.359

View more
  22 in total

Review 1.  A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.

Authors:  Josephine Mauskopf; Lieven Annemans; Andrew M Hill; Erik Smets
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 2.  The impact of disease stage on direct medical costs of HIV management: a review of the international literature.

Authors:  Adrian Levy; Karissa Johnston; Lieven Annemans; Andrea Tramarin; Julio Montaner
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 3.  Economic models of antiretroviral therapy: searching for the optimal strategy.

Authors:  Fred J Hellinger
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Counting the cost of not costing HIV health facilities accurately: pay now, or pay more later.

Authors:  Eduard J Beck; Carlos Avila; Sofia Gerbase; Guy Harling; Paul De Lay
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

Review 5.  Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries.

Authors:  Omar Galárraga; Veronika J Wirtz; Alejandro Figueroa-Lara; Yared Santa-Ana-Tellez; Ibrahima Coulibaly; Kirsi Viisainen; Antonieta Medina-Lara; Eline L Korenromp
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

Review 6.  HIV disease and advanced age: an increasing therapeutic challenge.

Authors:  Roberto Manfredi
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 7.  Economic costs to business of the HIV/AIDS epidemic.

Authors:  Gordon G Liu; Jeff J Guo; Scott R Smith
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

8.  Use and cost of antiretrovirals in France 1995-2000: an analysis based on the Medical Dossier on Human Immunodeficiency (release 2) database.

Authors:  Yves A Flori; Marc le Vaillant
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  Indirect costs in ambulatory patients with HIV/AIDS in Spain: a pilot study.

Authors:  Juan Oliva; César Roa; Juan del Llano
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  The economic costs and health-related quality of life of people with HIV/AIDS in the Canary Islands, Spain.

Authors:  Julio Lopez-Bastida; Juan Oliva-Moreno; Lilisbeth Perestelo-Perez; Pedro Serrano-Aguilar
Journal:  BMC Health Serv Res       Date:  2009-03-30       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.